Literature DB >> 8601376

Granulomatous hepatitis associated with glyburide.

D Saw1, E Pitman, M Maung, P Savasatit, D Wasserman, C K Yeung.   

Abstract

A wide variety of diseases and injuries can cause granulomatous hepatitis, and drug-induced granulomatous hepatitis is a well-described entity. Sulfonylurea derivatives, which are commonly used oral hypoglycemic agents in the treatment of non-insulin-dependent diabetes mellitus, have been implicated in liver disease. However, glyburide, a second-generation sulfonylurea and a potent hypoglycemic drug, is considered to have less hepatic side effects than chlorpropamide. It has been reportedly associated with cholestatic jaundice and hepatitis and with hypersensitivity angitis. A case of necrotizing granuloma has been reported. We present a second case of granulomatous hepatitis occurring in a patient who had been taking glyburide for approximately three years, and we review the literature for glyburide-associated hepatitis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8601376     DOI: 10.1007/bf02093822

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  8 in total

1.  Glyburide-induced hepatitis.

Authors:  P Meadow; C J Tullio
Journal:  Clin Pharm       Date:  1989-07

2.  Clinical, cellular, and physiologic effects of glyburide in non-insulin-dependent diabetes mellitus.

Authors:  J M Olefsky
Journal:  Am J Med       Date:  1985-09-20       Impact factor: 4.965

3.  Generalized hypersensitivity reaction and visceral arteritis with fatal outcome during glibenclamide therapy.

Authors:  B F Clarke; I W Campbell; D J Ewing; G W Beveridge; M K MacDonald
Journal:  Diabetes       Date:  1974-09       Impact factor: 9.461

4.  Drug-induced granulomatous hepatitis.

Authors:  K R McMaster; G R Hennigar
Journal:  Lab Invest       Date:  1981-01       Impact factor: 5.662

5.  Glyburide-induced hepatitis.

Authors:  R C Goodman; P J Dean; A Radparvar; A E Kitabchi
Journal:  Ann Intern Med       Date:  1987-06       Impact factor: 25.391

6.  Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.

Authors:  V Wongpaitoon; P R Mills; R I Russell; R S Patrick
Journal:  Postgrad Med J       Date:  1981-04       Impact factor: 2.401

Review 7.  Glyburide-induced cholestatic hepatitis and liver failure. Case-report and review of the literature.

Authors:  J P van Basten; B van Hoek; R Zeijen; R Stockbrügger
Journal:  Neth J Med       Date:  1992-06       Impact factor: 1.422

8.  [Hypersensitivity vasculitis and granulomatous hepatitis induced by glybenclamide: a case report (author's transl)].

Authors:  M Ingelmo; J Vivancos; M Bruguera; J Sierra; A Balcells
Journal:  Med Clin (Barc)       Date:  1980-10-25       Impact factor: 1.725

  8 in total
  2 in total

1.  Solitary Hepatic Eosinophilic Granuloma Accompanied by Eosinophilia Without Parasitosis: Report of a Case.

Authors:  Takatsugu Yamamoto; Toru Miyazaki; Yukiko Kurashima; Kazunori Ohata; Masato Okawa; Shogo Tanaka; Takahiro Uenishi; Katsuhiko Miyaji; Nobusuke Fukumoto
Journal:  Int Surg       Date:  2015-06

2.  Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US.

Authors:  Keith G Tolman; James W Freston; Stuart Kupfer; Alfonso Perez
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.